For 1,000 patients undergoing hip replacement, apixaban resulted in 3,556.1 discounted QALYs, compared with 3,556.6 QALYs with rivaroxaban, 3,551.1 with dabigatran, and 3,550.1 with enoxaparin. For 1,000 patients undergoing knee replacement, apixaban resulted in 3,520.8 discounted QALYs, compared with 3,524.9 QALYs with rivaroxaban, 3,508.1 with dabigatran, and 3,506.8 with enoxaparin.
For hip replacement, the cost was £199,650 with apixaban, £234,710 with rivaroxaban, £262,381 with dabigatran, and £430,892 with enoxaparin. For knee replacement, the cost was £251,162 with apixaban, £242,676 with rivaroxaban, £339,230 with dabigatran, and £462,912 with enoxaparin.
The treatment alternatives ranked differently according to QALYs, life years gained, total venous thromboembolisms and total bleeding events, with apixaban or rivaroxaban being the preferred options. Apixaban avoided more bleeding events, but rivaroxaban avoided more venous thromboembolisms.